Management of Diabetes Mellitus Patients With Retinopathy

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00828425
First received: January 23, 2009
Last updated: August 17, 2010
Last verified: August 2010
  Purpose

Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed:

  • which medication are used to keep blood pressure under control?
  • which medication are used for metabolic control?
  • the average control level of metabolism and blood pressure is compliant with the international guidelines?
  • laser photocoagulation plays a role in the control of metabolism and blood pressure?
  • there are differences in the control of metabolism and blood pressure between patients with DM I or DM II?
  • there is an influence of renal failure on the choose of medication?

Condition
Retinopathy
Diabetes Mellitus

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Management of Diabetes Mellitus Patients With Retinopathy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
  • evolution of diabetic retinopathy [ Time Frame: every 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • concomitant medication [ Time Frame: every 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: December 2008
Study Completion Date: August 2009
Groups/Cohorts
1
Diabetic patients with retinopathy

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Diabetic patients with diabetic retinopathy

Criteria

Inclusion Criteria:

  • Diabetic patients
  • Diabetic retinopathy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00828425

  Hide Study Locations
Locations
Switzerland
Research Site
Dattwil, AG, Switzerland
Research Site
Hausen b. Brugg, AG, Switzerland
Research Site
Lenzburg, AG, Switzerland
Research Site
Lupfig, AG, Switzerland
Research Site
Muri AG, AG, Switzerland
Research Site
Rheinfelden, AG, Switzerland
Research Site
Schinznach Dorf, AG, Switzerland
Research Site
Spreitenbach, AG, Switzerland
Research Site
Bern, BE, Switzerland
Research Site
Moutier, BE, Switzerland
Research Site
Unterseen, BE, Switzerland
Research Site
Diegten, BL, Switzerland
Research Site
Laufen, BL, Switzerland
Research Site
Basel, BS, Switzerland
Research Site
Estavayer-le-Lac, FR, Switzerland
Research Site
Fribourg, FR, Switzerland
Research Site
Collonge-Bellerive, GE, Switzerland
Research Site
Geneve, GE, Switzerland
Research Site
Le Grand-Saconnex, GE, Switzerland
Research Site
Les Acacias, GE, Switzerland
Research Site
Versoix, GE, Switzerland
Research Site
Chur, GR, Switzerland
Research Site
Ilanz, GR, Switzerland
Research Site
Samedan, GR, Switzerland
Research Site
Alle, JU, Switzerland
Research Site
Luzern, LU, Switzerland
Research Site
Rothenburg, LU, Switzerland
Research Site
Le Locle, NE, Switzerland
Research Site
Kerns, OW, Switzerland
Research Site
Oberuzwil, SG, Switzerland
Research Site
Rorschach, SG, Switzerland
Research Site
St. Gallen, SG, Switzerland
Research Site
Wangs, SG, Switzerland
Research Site
Schaffhausen, SH, Switzerland
Research Site
Kussnacht am Rigi, SZ, Switzerland
Research Site
Tuggen, SZ, Switzerland
Research Site
Kreuzlingen, TG, Switzerland
Research Site
Ascona, TI, Switzerland
Research Site
Locarno, TI, Switzerland
Research Site
Lugano, TI, Switzerland
Research Site
Viganello, TI, Switzerland
Research Site
Aigle, VD, Switzerland
Research Site
Bassins, VD, Switzerland
Research Site
Bex, VD, Switzerland
Research Site
Chateau-d'Oex, VD, Switzerland
Research Site
Clarens, VD, Switzerland
Research Site
Eysins, VD, Switzerland
Research Site
Lausanne, VD, Switzerland
Research Site
Nyon, VD, Switzerland
Research Site
Prilly, VD, Switzerland
Research Site
Renens VD, VD, Switzerland
Research Site
Salavaux, VD, Switzerland
Research Site
St-Legier, VD, Switzerland
Research Site
Vevey, VD, Switzerland
Research Site
Ardon, VS, Switzerland
Research Site
Evionnaz, VS, Switzerland
Research Site
Saviese, VS, Switzerland
Research Site
Sierre, VS, Switzerland
Research Site
Sion, VS, Switzerland
Research Site
Bassersdorf, ZH, Switzerland
Research Site
Egg b. Zurich, ZH, Switzerland
Research Site
Winterthur, ZH, Switzerland
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: Dr. Med. Dirk Schneider - Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00828425     History of Changes
Other Study ID Numbers: NIS-CCH-DUM-2008/1
Study First Received: January 23, 2009
Last Updated: August 17, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
Diabetes Mellitus
retinopathy
Management of diabetic patients with retinopathy

Additional relevant MeSH terms:
Diabetes Mellitus
Retinal Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Eye Diseases

ClinicalTrials.gov processed this record on April 15, 2014